Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Newly Diagnosed CP-CML (PhilosoPhi34)
NCT01856283Phase 2Completed
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Mar 2013
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib in chronic myeloid leukemia (CML), sponsored by ASST Grande Ospedale Metropolitano Niguarda. Started Mar 2013; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01856283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01856283.